<DOC>
	<DOCNO>NCT00025636</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know combination chemotherapy regimen give peripheral stem cell transplant effective treating relapse Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial compare different regimen combination chemotherapy follow peripheral stem cell transplant see well work treat patient relapse Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplant Treating Patients With Relapsed Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy induction chemotherapy follow combination chemotherapy autologous peripheral blood stem cell transplantation without high-dose sequential chemotherapy term freedom treatment failure patient relapse Hodgkin 's lymphoma . - Compare toxicity regimens patient . - Compare complete remission/unconfirmed complete remission rate 3 month , relapse-free survival , overall survival patient treat regimen . - Compare frequency severe toxic effect secondary neoplasia patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , type relapse ( early first relapse [ remission duration 3-12 month ] v late first relapse [ remission duration 12 month ] vs second relapse without prior high-dose chemotherapy salvage [ remission duration salvage least 3 month ] ) , disease status relapse ( stage I II v stage III IV ) , age ( 18 49 v 50 60 ) , response 2 course study induction chemotherapy ( complete remission v partial remission v change ) . All patient receive induction chemotherapy comprise dexamethasone IV 30 minute day 1-4 15-18 , cisplatin IV continuously 24 hour day 1 15 , cytarabine IV 3 hour every 12 hour day 2 16 , filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 5-12 day 19-26 . Patients complete remission ( CR ) , unconfirmed CR , partial remission , change randomize one two treatment arm . - Arm I : Patients receive BEAM chemotherapy comprise carmustine IV 30 minute melphalan IV 30 minute day 37 etoposide IV 30 minute every 12 hour cytarabine IV 30 minute every 12 hour day 37-40 . Patients also receive G-CSF SC twice daily begin day 41 continue blood count recover . Autologous peripheral blood stem cell ( PBSCs ) reinfused day 42 . - Arm II : Patients receive high-dose cyclophosphamide IV 8 hour day 37 , high-dose methotrexate IV 6 hour high-dose vincristine IV day 51 , high-dose etoposide IV 8 hour day 58-61 . Patients receive BEAM chemotherapy comprise carmustine IV 30 minute melphalan IV 30 minute day 80 etoposide IV 30 minute every 12 hour cytarabine IV 30 minute every 12 hour day 80-83 . Patients also receive G-CSF SC day 38 62 twice daily begin day 84 continue blood count recover . Autologous PBSCs reinfused day 85 . Patients residual lymphoma 100 day completion BEAM chemotherapy may receive radiotherapy . Patients follow 100 day PBSC transplantation , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A minimum 220 patient ( 110 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's lymphoma Early late first relapse Complete partial remission least 3 month completion prior COPP/ABVD , COPP/ABV/IMEP , MOPP/ABV , ABVD , BEACOPP , polychemotherapy regimen without radiotherapy No prior salvage therapy OR Second relapse Any prior salvage therapy No prior highdose chemotherapy PATIENT CHARACTERISTICS : Age : 18 60 Performance status : Karnofsky 70100 % OR ECOG 02 Life expectancy : More 3 month treatment Hematopoietic : Absolute neutrophil count least 2,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Not specify Renal : Creatinine clearance least 60 mL/min Cardiovascular : No uncontrolled hypertension ( diastolic blood pressure great 115 mm Hg ) No unstable angina No New York Heart Association class III IV heart disease ( congestive heart failure ) No myocardial infarction within past 6 month No uncontrolled atrial ventricular cardiac arrhythmia Pulmonary : No chronic pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No active infection No poorly control diabetes No cerebral disorder No concurrent malignancy except adequately treat basal cell skin cancer cervical intraepithelial neoplasia No significant nonmalignant disease No psychiatric , addictive , disorder would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : At least 6 month since prior coronary angioplasty No concurrent investigational drug No concurrent nonsteroidal antiinflammatory drug , salicylate , sulfonamide , trimethoprim , allopurinol , aminoglycoside , amoxicillin , probenecid highdose methotrexate administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>